Terns Pharmaceuticals Stock Buy Hold or Sell Recommendation
| TERN Stock | USD 6.24 0.10 1.58% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Terns Pharmaceuticals is 'Sell'. The recommendation algorithm takes into account all of Terns Pharmaceuticals' available fundamental, technical, and predictive indicators you will find on this site.
Check out Terns Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide. In addition, we conduct extensive research on individual companies such as Terns and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Terns Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Terns |
Execute Terns Pharmaceuticals Buy or Sell Advice
The Terns recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Terns Pharmaceuticals. Macroaxis does not own or have any residual interests in Terns Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Terns Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Sell
Market Performance | Very Weak | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Average | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Terns Pharmaceuticals Trading Alerts and Improvement Suggestions
| Terns Pharmaceuticals generated a negative expected return over the last 90 days | |
| Terns Pharmaceuticals has high historical volatility and very poor performance | |
| Terns Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (90.21 M) with profit before overhead, payroll, taxes, and interest of 1000 K. | |
| Terns Pharmaceuticals currently holds about 139.81 M in cash with (67.39 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.51. | |
| Terns Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Terns Pharmaceuticals Stock Surges Over 5 percent Amid Biotech Sector Gains |
Terns Pharmaceuticals Returns Distribution Density
The distribution of Terns Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Terns Pharmaceuticals' future price movements. The chart of the probability distribution of Terns Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Terns Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Terns Pharmaceuticals returns is essential to provide solid investment advice for Terns Pharmaceuticals.
| Mean Return | -0.2 | Value At Risk | -5.96 | Potential Upside | 6.02 | Standard Deviation | 5.08 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Terns Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Terns Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Terns Pharmaceuticals, soars without any apparent reason. This usually happens because many institutional investors are aggressively trading Terns Pharmaceuticals back and forth among themselves. Companies that invest excess capital in these types of assets may also be included in this term and can influence corporate governance by exercising voting rights in their investments.
| Shares | Exoduspoint Capital Management, Lp | 2024-09-30 | 1.6 M | Superstring Capital Management Lp | 2024-09-30 | 1.3 M | Geode Capital Management, Llc | 2024-09-30 | 1.2 M | State Street Corp | 2024-06-30 | 1.2 M | Fmr Inc | 2024-09-30 | 1.2 M | Great Point Partners Llc | 2024-06-30 | 1.1 M | Millennium Management Llc | 2024-06-30 | 1.1 M | Driehaus Capital Management Llc | 2024-06-30 | 1.1 M | Bellevue Group Ag | 2024-09-30 | 1 M | Orbimed Advisors, Llc | 2024-06-30 | 7.6 M | Vivo Capital, Llc | 2024-09-30 | 6.9 M |
Terns Pharmaceuticals Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Investments | (3.0M) | 7.3M | (119.4M) | (22.0M) | (38.0M) | (39.9M) | |
| Change In Cash | (70.1M) | 62.5M | (27.2M) | 95.5M | (63.3M) | (60.1M) | |
| Free Cash Flow | (67.1M) | (30.4M) | (42.2M) | (49.4M) | (67.4M) | (70.8M) | |
| Depreciation | 195K | 394K | 512K | 1.0M | 881K | 564.5K | |
| Other Non Cash Items | (246K) | 2.9M | 879K | 81K | (5.0M) | (4.8M) | |
| Capital Expenditures | 900K | 584K | 340K | 275K | 52K | 49.4K | |
| Net Income | (68.8M) | (40.6M) | (50.2M) | (60.3M) | (90.2M) | (85.7M) | |
| End Period Cash Flow | 12.4M | 74.9M | 47.7M | 143.2M | 79.9M | 80.8M | |
| Change To Netincome | 326K | (5.9M) | 9.2M | 10.8M | 12.4M | 13.0M |
Terns Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Terns Pharmaceuticals or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Terns Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Terns stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.33 | |
β | Beta against Dow Jones | 0.96 | |
σ | Overall volatility | 5.16 | |
Ir | Information ratio | -0.07 |
Terns Pharmaceuticals Volatility Alert
Terns Pharmaceuticals exhibits very low volatility with skewness of 1.9 and kurtosis of 7.38. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Terns Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Terns Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Terns Pharmaceuticals Fundamentals Vs Peers
Comparing Terns Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Terns Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Terns Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Terns Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Terns Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Terns Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Terns Pharmaceuticals to competition |
| Fundamentals | Terns Pharmaceuticals | Peer Average |
| Return On Equity | -0.28 | -0.31 |
| Return On Asset | -0.19 | -0.14 |
| Current Valuation | 167.04 M | 16.62 B |
| Shares Outstanding | 84.94 M | 571.82 M |
| Shares Owned By Insiders | 0.13 % | 10.09 % |
| Shares Owned By Institutions | 97.72 % | 39.21 % |
| Number Of Shares Shorted | 3.98 M | 4.71 M |
| Price To Book | 1.48 X | 9.51 X |
| Price To Sales | 302.64 X | 11.42 X |
| Gross Profit | 1000 K | 27.38 B |
| EBITDA | (102.56 M) | 3.9 B |
| Net Income | (90.21 M) | 570.98 M |
| Cash And Equivalents | 139.81 M | 2.7 B |
| Cash Per Share | 5.51 X | 5.01 X |
| Total Debt | 603 K | 5.32 B |
| Debt To Equity | 0.01 % | 48.70 % |
| Current Ratio | 23.59 X | 2.16 X |
| Book Value Per Share | 4.29 X | 1.93 K |
| Cash Flow From Operations | (67.39 M) | 971.22 M |
| Short Ratio | 3.16 X | 4.00 X |
| Earnings Per Share | (1.18) X | 3.12 X |
| Target Price | 18.19 | |
| Number Of Employees | 66 | 18.84 K |
| Beta | -0.33 | -0.15 |
| Market Capitalization | 538.51 M | 19.03 B |
| Total Asset | 268.52 M | 29.47 B |
| Retained Earnings | (332.63 M) | 9.33 B |
| Working Capital | 255.49 M | 1.48 B |
| Net Asset | 268.52 M |
Note: Acquisition by Orbimed Advisors Llc of 2470200 shares of Terns Pharmaceuticals at 2.42 subject to Rule 16b-3 [view details]
Terns Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Terns . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 39605.07 | |||
| Daily Balance Of Power | (0.28) | |||
| Rate Of Daily Change | 0.98 | |||
| Day Median Price | 6.21 | |||
| Day Typical Price | 6.22 | |||
| Price Action Indicator | (0.02) | |||
| Period Momentum Indicator | (0.10) | |||
| Relative Strength Index | 52.94 |
About Terns Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Terns Pharmaceuticals? Buying financial instruments such as Terns Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Terns Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Target Risk ETFs Thematic Idea Now
Target Risk ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Target Risk ETFs theme has 32 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Target Risk ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Terns Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Terns Pharmaceuticals. If investors know Terns will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Terns Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.18) | Revenue Per Share 0.035 | Return On Assets (0.19) | Return On Equity (0.28) |
The market value of Terns Pharmaceuticals is measured differently than its book value, which is the value of Terns that is recorded on the company's balance sheet. Investors also form their own opinion of Terns Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Terns Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Terns Pharmaceuticals' market value can be influenced by many factors that don't directly affect Terns Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Terns Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Terns Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Terns Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.